Experience of switching biological therapy in a patient with juvenile idiopathic arthritis and uveitis. Case report

Cover Page

Cite item

Abstract

Uveitis associated with juvenile arthritis can be complicated by cataracts, retinal edema, and glaucoma, which carries a potential risk of disability in the child's organ of vision. Approximately 25–40% of patients demonstrate insufficient effectiveness of the ongoing standard antirheumatic therapy, which requires the inclusion of genetically engineered biological therapy. According to the protocols, the drug of choice for juvenile arthritis associated with uveitis is adalimumab, which has shown high efficacy in many studies. However, some patients stop “responding” to therapy over time, which raises the question of “switching” to another genetically engineered biological drug (GЕBD). Our article presents a case of severe course with an early onset of juvenile idiopathic arthritis associated with uveitis. Due to the insufficient effectiveness of basic monotherapy with methorexate, as well as topical glucocorticoids, adilimumab was added to therapy a year after the onset of the disease. Over the next 5 years, the child was on this therapy with exacerbations of uveitis about 1–2 episodes per year. Subsequently, uveitis began to continuously recur, which raised the question of the development of probable resistance to adalimumab and the change of GEBD. The girl was switched to golimumab, which is a human monoclonal antibody that can bind to tumor necrosis factor-α. This drug has been used for the treatment of juvenile idiopathic arthritis since 2017 for children weighing 40 kg and above, and after the completion of the multicenter GO-KIDS study, it is registered for children from 2 years of age. According to a number of studies, golimumab has shown its effectiveness in relation to the activity of uveitis in patients with arthritis, including those in childhood. In general, the issues of switching GEBD in cases of ineffective therapy with first-line drugs are a very urgent problem in pediatric rheumatology. In our case, switching to the GIBP golimumab resulted in a positive effect on the activity of rheumatoid uveitis and induction of remission of the articular syndrome.

Full Text

Restricted Access

About the authors

Lelia A. Galstian

Sechenov First Moscow State Medical University (Sechenov University)

Author for correspondence.
Email: vesna-catu@mail.ru
ORCID iD: 0000-0002-5616-3998

Cand. Sci. (Med.), Sechenov First Moscow State Medical University (Sechenov University)

Russian Federation, Moscow

Maksim V. Verbitsky

Sechenov First Moscow State Medical University (Sechenov University)

Email: vesna-catu@mail.ru

Student, Sechenov First Moscow State Medical University (Sechenov University)

Russian Federation, Moscow

Angelina V. Polyanskaya

Sechenov First Moscow State Medical University (Sechenov University)

Email: meleshkina.angel@mail.ru
ORCID iD: 0000-0002-4125-0335

Cand. Sci. (Med.), Sechenov First Moscow State Medical University (Sechenov University)

Russian Federation, Moscow

Svetlana N. Chebysheva

Sechenov First Moscow State Medical University (Sechenov University)

Email: svetamma@gmail.com
ORCID iD: 0000-0001-5669-4214

Cand. Sci. (Med.), Sechenov First Moscow State Medical University (Sechenov University)

Russian Federation, Moscow

Mariya A. Kudryashova

Sechenov First Moscow State Medical University (Sechenov University)

Email: vesna-catu@mail.ru
ORCID iD: 0000-0001-7275-4344

Cand. Sci. (Med.), Sechenov First Moscow State Medical University (Sechenov University)

Russian Federation, Moscow

Oksana V. Batyreva

Sechenov First Moscow State Medical University (Sechenov University)

Email: vesna-catu@mail.ru

Cand. Sci. (Med.), Sechenov First Moscow State Medical University (Sechenov University)

Russian Federation, Moscow

Margarita I. Tikhaya

Sechenov First Moscow State Medical University (Sechenov University)

Email: vesna-catu@mail.ru
ORCID iD: 0000-0002-4158-8782

rheumatologist, Sechenov First Moscow State Medical University (Sechenov University)

Russian Federation, Moscow

Elena S. Zholobova

Sechenov First Moscow State Medical University (Sechenov University)

Email: vesna-catu@mail.ru
ORCID iD: 0000-0002-2835-2839

D. Sci. (Med.), Prof., Sechenov First Moscow State Medical University (Sechenov University)

Russian Federation, Moscow

References

  1. Kasper M, Walscheid K, Laffer B, et al. Phenotype of Innate Immune Cells in Uveitis Associated with Axial Spondyloarthritis- and Juvenile Idiopathic Arthritis-associated Uveitis. Ocul Immunol Inflamm. 2021;29(6):1080-9.
  2. Галстян Л.А., Жолобова Е.С., Чебышева С.Н., и др. Увеит, ассоциированный с ювенильным идиопатическим артритом. Российский вестник перинатологии и педиатрии. 2019;64(2):30-7 [Galstyan LA, Zholobova ES, Chebysheva SN, et al. Uveitis associated with juvenile idiopathic arthritis. Rossiyskiy Vestnik Perinatologii i Pediatrii. 2019;64(2):30-7 (in Russian)].
  3. Kingsbury DJ, Bader-Meunier B, Patel G, et al. Safety, effectiveness and pharmacokinetics of adalimumab in children with polyarticular juvenile idiopathic arthritis aged 2to4years. Clin Rheumatol. 2014;33(10):1433-41. doi: 10.1007/s10067-014-2498-1
  4. Simonini G, Druce K, Cimaz R, et al. Curent evidence of anti-tumor necrosis factor alpha treatment efficacy in childhood chronic uveitis: a systematic review and meta-analysis approach of individual drugs. Arthritis Care Res (Hoboken). 2014;66(7):1073-84. doi: 10.1002/acr22214
  5. Hawkins MJ, Dick AD, Lee RJ, et al. Managing juvenile idiopathic arthritis-associated uveitis. Surv Ophthalmol. 2016;61(2):197-210.
  6. Mérida S, Palacios E, Navea A, Bosch-Morell F. New Immunosuppressive Therapies in Uveitis Treatment. Intl J Mol Sci. 2015;16(8):18778-95.
  7. Баранов А.А., Алексеева Е.И., Бзарова Т.М., и др. Протокол ведения пациентов с ювенильным артритом. Вопросы современной педиатрии. 2013;12(1):37-56 [Baranov AA, Alekseeva EI, Bzarova TM, et al. Management protocol for patients with juvenile arthritis. Current Pediatrics. 2013;12(1):37-56 (in Russian)].
  8. Жолобова Е.С., Игнатова А.К., Сейланова Н.Г., и др. Выбор и переключение генноинженерных биологических препаратов в лечении ювенильного артрита. Педиатрия им. Г.Н. Сперанского. 2018;97(3):52-61 [Zholobova ES, Ignatova AK, Seylanova NG, et al. Selection and switching of genetically engineered biological agents in treatment of juvenile arthritis. Pediatrics n. a. GN Speransky. 2018;97(3):52-61 (in Russian)].
  9. Алексеева Е.И., Митенко Е.В., Валиева С.И., и др. Эффективность и безопасность терапии адалимумабом у детей с ювенильным идиопатическим артритом и увеитом. Вопросы современной педиатрии. 2012;11(1):111-8 [Alexeeva EI, Mitenko EV, Valieva SI, et al. Efficacy and safety of pediatric juvenile idiopathic arthritis and uveitis treatment with adalimumab. Current Pediatrics. 2012;11(1):111-8 (in Russian)].
  10. Галстян Л.А. Сравнительная оценка эффективности и безопасности генно-инженерных биологических препаратов в лечении ювенильного идиопатического артрита с поражением глаз. Автореф. дис. … канд. мед. наук. М., 2018 [Galstian LA. Sravnitel'naia otsenka effektivnosti i bezopasnosti genno-inzhenernykh biologicheskikh preparatov v lechenii iuvenil'nogo idiopaticheskogo artrita s porazheniem glaz. Avtoref. dis. … kand. med. nauk. Moscow, 2018 (in Russian)].
  11. Михельс Х., Никишина И.П., Федоров Е.С., Салугина С.О. Генно-инженерная биологическая терапия ювенильного артрита. Научно-практическая ревматология. 2011;1:78-93 [Michels H, Nikishina IP, Fedorov ES, Salugina SO. Gene engineering biological therapy for juvenile arthritis. Nauchno-prakticheskaia revmatologiia. 2011;1:78-93 (in Russian)].
  12. Денисова Р.В., Алексеева Е.И. Новый блокатор ФНО – голимумаб. Обзор результатов исследований по оценке эффективности и безопасности. Вопросы современной педиатрии. 2012;11(4):14-20 [Denisova RV, Alexeeva EI. Golimumab – a new TNF α-blocker. the review of the efficacy and safety evaluation results. Current Pediatrics. 2012;11(4):14-20 (in Russian)].
  13. Brunner HI, Ruperto N, Tzaribachev N, et al. Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicentre, double-blind, randomised-withdrawal trial. Ann Rheum Dis. 2018;77(1):21-9. doi: 10.1136/annrheumdis-2016-210456
  14. Кучинская Е.М., Костик М.М., Снегирева Л.С., и др. Эффективность применения препарата голимумаб у детей с полиартикулярным вариантом ювенильного идиопатического артрита. Педиатр. 2014;5(4):48-52 [Kuchinskaia EM, Kostik MM, Snegireva LS, et al. Effektivnost' primeneniia preparata golimumab u detei s poliartikuliarnym variantom iuvenil'nogo idiopaticheskogo artrita. Pediatr. 2014;5(4):48-52 (in Russian)].
  15. Денисова Р.В., Алексеева Е.И., Дворяковская Т.М., и др. Переключение на второй ингибитор TNF у пациента с тяжелым течением юношеского полиартрита: клинический случай. Вопросы современной педиатрии. 2018;17(4):328-32 [Denisova EV, Alexeeva EI, Dvoryakovskaya TM, et al. Switching to a Second TNF-α Inhibitor in a Patient with Severe Juvenile Polyarthritis: A Clinical Case. Current Pediatrics. 2018;17(4):328-32 (in Russian)].
  16. Palmou-Fontana N, Calvo-Río V, Martín-Varillas JL, et al. Golimumab in refractory uveitis associated to juvenile idiopathic arthritis: multicentre study of 7 cases and literature review. Clin Exp Rheumatol. 2018;36(4):652-7.
  17. Lanz S, Seidel G, Skrabl-Baumgartner A. Golimumab in juvenile idiopathic arthritis-associated uveitis unresponsive to Adalimumab. Pediatr Rheumatol. 2021;19:132. doi: 10.1186/s12969-021-00630-1
  18. Mridula W, Sepideh F, Papaliodis GN. Lobo A-M. Golimumab for the treatment of refractory juvenile idiopathic arthritis-associated uveitis. J Ophthalmic Inflamm Infect. 2012;2(4):231-3.

Copyright (c) 2022 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 74329 от 19.11.2018 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies